Publications by Magdalena Malm
Peer reviewed
Articles
[1]
N. Thalén et al., "Mammalian cell display with automated oligo design and library assembly allows for rapid residue level conformational epitope mapping," Communications Biology, vol. 7, no. 1, 2024.
[2]
N. Thalén et al., "Tuning of CHO secretional machinery improve activity of secreted therapeutic sulfatase 150-fold," Metabolic engineering, vol. 81, pp. 157-166, 2024.
[3]
C. D. Leitao et al., "Display of a naïve affibody library on staphylococci for selection of binders by means of flow cytometry sorting," Biochemical and Biophysical Research Communications - BBRC, vol. 655, pp. 75-81, 2023.
[4]
M. Moradi et al., "Autophagy and intracellular product degradation genes identified by systems biology analysis reduce aggregation of bispecific antibody in CHO cells," New Biotechnology, vol. 68, pp. 68-76, 2022.
[5]
M. Malm et al., "Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins," Metabolic engineering, vol. 72, pp. 171-187, 2022.
[6]
R. Saghaleyni et al., "Report Enhanced metabolism and negative regulation of ER stress support higher erythropoietin production in HEK293 cells," Cell Reports, vol. 39, no. 11, pp. 110936, 2022.
[7]
M. Malm et al., "Evolution from adherent to suspension : systems biology of HEK293 cell line development," Scientific Reports, vol. 10, no. 1, 2020.
[8]
C. Zhan et al., "Low Shear Stress Increases Recombinant Protein Production and High Shear Stress Increases Apoptosis in Human Cells," iScience, vol. 23, no. 11, 2020.
[9]
H. Schwarz et al., "Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant Erythropoietin," Journal of Biotechnology, vol. 309, pp. 44-52, 2020.
[10]
[11]
M. Malm et al., "Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds," mAbs, vol. 8, no. 7, pp. 1195-1209, 2016.
[12]
K. G. Andersson et al., "Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors," Oncology Reports, vol. 34, no. 2, pp. 1042-8, 2015.
[13]
M. Malm et al., "Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension," Biotechnology Journal, vol. 9, no. 9, pp. 1215-1222, 2014.
[14]
A. Orlova et al., "Imaging of HER3-expressing xenografts in mice using a Tc-99m(CO)(3)-HEHEHE-Z(HER3:08699) affibody molecule," European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 7, pp. 1450-1459, 2014.
[15]
M. Malm et al., "Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification," PLOS ONE, vol. 8, no. 5, pp. e62791, 2013.
[16]
L. Göstring et al., "Cellular Effects of HER3-Specific Affibody Molecules," PLOS ONE, vol. 7, no. 6, pp. e40023, 2012.
[17]
N. Kronqvist et al., "Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules," Protein Engineering Design & Selection, vol. 24, no. 4, pp. 385-396, 2011.
[18]
N. Kronqvist et al., "Staphylococcal surface display in combinatorial protein engineering and epitope mapping of antibodies," Recent Patents on Biotechnology, vol. 4, no. 3, pp. 171-182, 2010.
Non-peer reviewed
Articles
[19]
M. Malm et al., "Improving targeting and yield of AAV by capsid and cell engineering," Human Gene Therapy, vol. 32, no. 19-20, pp. A119-A120, 2021.
[20]
K. G. Andersson et al., "111In-labeled NOTA-conjugated Affibody molecules for visualization of HER3 expression in malignant tumors," European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, pp. S311-S311, 2014.
[21]
A. Orlova et al., "Feasibility of radionuclide imaging of HER3-expressing tumors using affibody molecules," Journal of labelled compounds & radiopharmaceuticals, vol. 56, pp. S11-S11, 2013.
[22]
A. Orlova et al., "Feasibility of radionuclide imaging of HER3-expressing tumours using technetium-99m labeled affibody molecules," European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, pp. S185-S186, 2013.
Theses
[23]
M. Malm, "Generation and characterization of Affibody molecules targeting HER3," Doctoral thesis Stockholm : KTH Royal Institute of Technology, TRITA-BIO-Report, 2014:1, 2013.
Other
[24]
H. Thorell et al., "A modular binding domain AAV platform for cell surface receptor-selective DNA delivery," (Manuscript).
[25]
M. Karlander et al., "Amplification and Fragmentation Free Long-read Sequencing Enables Rapid Analysis of Packaged Adeno-associated Virus ssDNA," (Manuscript).
[26]
[27]
M. Malm et al., "Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins," (Manuscript).
[28]
C. Zhan et al., "Hydrodynamic shear stress in hollow filter for perfusion culture of human cells," (Manuscript).
[29]
H. Schwarz et al., "Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant Erythropoietin," (Manuscript).
[30]
M. Karlander et al., "Survival of the less fit - directed evolution via deep sequencing enables selection of diverse high affinity proteins," (Manuscript).
[31]
N. Thalén et al., "Systems biology greatly improve activity of secreted therapeutic sulfatase in CHO bioprocess," (Manuscript).
Latest sync with DiVA:
2025-01-12 01:41:41